Propanc Biopharma, Inc. (PPCB) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.2x

Market Cap

$2.30M

MomentumView details →

1D Return

−0.98%

YTD Return

−92.56%

RSI (14)

44.0

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.2x

Market Cap

$2.30M

RSI (14)

44.0

MomentumView details →

1D Return

−0.98%

YTD Return

−92.56%

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−186.82%

ROA (TTM)

−128.10%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+95.47%

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

+98.95%

EBITDA YoY

+67.73%

EarningsView details →

EPS (Actual)

−$0.28

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.16x

Current Ratio

2.37x

Quick Ratio

2.37x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−18.36M

Op. CF (TTM)

−4.11M

Latest newsMore news →

Propanc Biopharma announced it has commenced finalization of a clinical trial protocol and will conduct a feasibility assessment for its First-In-Human Phase 1b clinical study of PRP in up to 40 advanced cancer patients with solid tumors.18d ago

Propanc Biopharma announced positive preclinical and early translational data for its lead candidate PRP in pancreatic ductal adenocarcinoma models, showing over 90% tumor growth inhibition and significant survival benefit.30d ago

Similar companies

BioXcel Therapeutics, Inc.BTAI CASI Pharmaceuticals, Inc.CASI Voyager Acquisition CorpVRXAW Clearside Biomedical, Inc.CLSD Virax Biolabs Group LimitedVRAX Silexion Therapeutics Ltd.SLXN Find similar companies →

Latest newsMore news →

Propanc Biopharma announced it has commenced finalization of a clinical trial protocol and will conduct a feasibility assessment for its First-In-Human Phase 1b clinical study of PRP in up to 40 advanced cancer patients with solid tumors.18d ago Propanc Biopharma announced positive preclinical and early translational data for its lead candidate PRP in pancreatic ductal adenocarcinoma models, showing over 90% tumor growth inhibition and significant survival benefit.30d ago Propanc Biopharma announced the completion of the first tranche of $500,000 of its $5.0 million share repurchase program within the first 30 days since commencing the program.31d ago